Actinium Pharmaceuticals, Inc.
ATNM
$1.26
$0.1614.55%
AMEX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | 11.11% | -- | -- | -- |
| Total Revenue | -- | 11.11% | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | 11.11% | -- | -- | -- |
| SG&A Expenses | 25.98% | 35.10% | 47.39% | 43.75% | -9.41% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -13.73% | -16.90% | -5.43% | -1.70% | -19.00% |
| Operating Income | 13.95% | 16.95% | 5.27% | 1.54% | 18.87% |
| Income Before Tax | 11.39% | 15.44% | 3.72% | 2.02% | 21.66% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 11.39% | 15.44% | 3.72% | 2.02% | 21.66% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 11.39% | 15.44% | 3.72% | 2.02% | 21.66% |
| EBIT | 13.95% | 16.95% | 5.27% | 1.54% | 18.87% |
| EBITDA | 14.17% | 17.22% | 5.36% | 1.50% | 19.14% |
| EPS Basic | 14.70% | 20.79% | 13.28% | 14.35% | 30.75% |
| Normalized Basic EPS | 14.70% | 20.81% | 13.30% | 14.37% | 30.76% |
| EPS Diluted | 14.70% | 20.79% | 13.28% | 14.35% | 30.75% |
| Normalized Diluted EPS | 14.70% | 20.81% | 13.30% | 14.37% | 30.76% |
| Average Basic Shares Outstanding | 3.76% | 7.13% | 10.84% | 13.80% | 13.03% |
| Average Diluted Shares Outstanding | 3.76% | 7.13% | 10.84% | 13.80% | 13.03% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |